Primecap Management Coca buys $4,445.9 Million stake in Amgen (AMGN)

Amgen (AMGN) : Primecap Management Coca scooped up 4,600 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 29,181,826 shares of Amgen which is valued at $4,445.9 Million.Amgen makes up approximately 4.99% of Primecap Management Coca’s portfolio.

Other Hedge Funds, Including , Trustmark National Bank Trust Department boosted its stake in AMGN in the latest quarter, The investment management firm added 318 additional shares and now holds a total of 9,461 shares of Amgen which is valued at $1.4 Million. Amgen makes up approx 0.20% of Trustmark National Bank Trust Department’s portfolio.Sandy Spring Bank reduced its stake in AMGN by selling 522 shares or 3.21% in the most recent quarter. The Hedge Fund company now holds 15,729 shares of AMGN which is valued at $2.4 Million. Amgen makes up approx 0.27% of Sandy Spring Bank’s portfolio.Capital Advisors Incok boosted its stake in AMGN in the latest quarter, The investment management firm added 1,936 additional shares and now holds a total of 69,877 shares of Amgen which is valued at $10.7 Million. Amgen makes up approx 1.73% of Capital Advisors Incok’s portfolio.Farmers Merchants Investments Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 3,943 additional shares and now holds a total of 22,130 shares of Amgen which is valued at $3.4 Million. Amgen makes up approx 0.39% of Farmers Merchants Investments Inc’s portfolio.

Amgen opened for trading at $148.92 and hit $151.71 on the upside on Friday, eventually ending the session at $150.18, with a gain of 1.02% or 1.51 points. The heightened volatility saw the trading volume jump to 30,76,109 shares. Company has a market cap of $112,817,769 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.